Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextromethorphan + promethazine is an oral combination drug comprising a **cough suppressant** (dextromethorphan) and a **first-generation antihistamine** (promethazine) used primarily for the **temporary relief of cough and upper respiratory symptoms** associated with allergies or the common cold[1][2][3][5][6][7][11]. - **Promethazine** acts as an H1 histamine receptor antagonist, providing antihistaminic, sedative, and antiemetic effects[3][6][8][9]. - **Dextromethorphan** is an antitussive agent that elevates the cough threshold by acting on the central nervous system[3][6][7]. The combination reduces symptoms such as cough, runny nose, sneezing, and red, itchy eyes[1][2][3][6][7][10]. The oral solution is contraindicated in children under 2 years due to severe respiratory risks[2][10][11]. Promethazine is structurally a phenothiazine derivative with antihistaminic, anticholinergic, and mild dopamine antagonist action[6][8]. Dextromethorphan is structurally related to morphinan derivatives but devoid of opioid and analgesic properties[7]. The combination is commonly available as an oral solution dosed every 4–6 hours as needed[1][2][3][11].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextromethorphan + promethazine.